BR0010802A - Antagonistas de receptor il-8 - Google Patents

Antagonistas de receptor il-8

Info

Publication number
BR0010802A
BR0010802A BR0010802-2A BR0010802A BR0010802A BR 0010802 A BR0010802 A BR 0010802A BR 0010802 A BR0010802 A BR 0010802A BR 0010802 A BR0010802 A BR 0010802A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
chemokine
receptor
binds
treating
Prior art date
Application number
BR0010802-2A
Other languages
English (en)
Inventor
Gregory Martin Benson
Robert P Hertzberg
Anthony J Jurewicz
Melvin Clarence Rutledge
Daniel F Veber
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0010802A publication Critical patent/BR0010802A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR IL-8". A presente invenção provê um método de tratar uma doença mediada por quimiocina, em que a quimiocina é uma que se liga a um receptor IL-8 <244> ou <225> e cujo método compreende administrar uma quantidade eficaz de um composto da Fórmula (I) ou um seu sal farmaceuticamente aceitável. Em particular, a quimiocina é IL-8.
BR0010802-2A 1999-06-16 2000-06-15 Antagonistas de receptor il-8 BR0010802A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16
PCT/US2000/016499 WO2000076495A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
BR0010802A true BR0010802A (pt) 2002-02-19

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010802-2A BR0010802A (pt) 1999-06-16 2000-06-15 Antagonistas de receptor il-8

Country Status (20)

Country Link
EP (1) EP1185261A4 (pt)
JP (1) JP2003501459A (pt)
KR (1) KR20020010709A (pt)
CN (1) CN1355697A (pt)
AR (1) AR030391A1 (pt)
AU (1) AU766083B2 (pt)
BR (1) BR0010802A (pt)
CA (1) CA2377341A1 (pt)
CO (1) CO5200760A1 (pt)
CZ (1) CZ20014471A3 (pt)
HK (1) HK1044483A1 (pt)
HU (1) HUP0201571A3 (pt)
IL (1) IL145761A0 (pt)
MX (1) MXPA01013004A (pt)
NO (1) NO20016053D0 (pt)
NZ (1) NZ514695A (pt)
PL (1) PL352232A1 (pt)
TR (1) TR200103680T2 (pt)
WO (1) WO2000076495A1 (pt)
ZA (1) ZA200109479B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
CA2493253A1 (en) * 2002-08-01 2004-02-12 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
EP1809619A1 (en) 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
AR056867A1 (es) 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (ja) * 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
KR100982661B1 (ko) * 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
KR100970940B1 (ko) * 2010-05-03 2010-07-20 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로 함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및 이를 이용한 말라리아 치료방법
US10093617B1 (en) 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
WO2000016768A1 (en) * 1998-09-18 2000-03-30 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
EP1185261A1 (en) 2002-03-13
PL352232A1 (en) 2003-08-11
CZ20014471A3 (cs) 2002-08-14
AR030391A1 (es) 2003-08-20
HK1044483A1 (zh) 2002-10-25
WO2000076495A1 (en) 2000-12-21
NZ514695A (en) 2004-05-28
KR20020010709A (ko) 2002-02-04
AU766083B2 (en) 2003-10-09
MXPA01013004A (es) 2002-07-30
ZA200109479B (en) 2002-11-18
JP2003501459A (ja) 2003-01-14
TR200103680T2 (tr) 2002-07-22
NO20016053L (no) 2001-12-11
CA2377341A1 (en) 2000-12-21
NO20016053D0 (no) 2001-12-11
IL145761A0 (en) 2002-07-25
CO5200760A1 (es) 2002-09-27
CN1355697A (zh) 2002-06-26
EP1185261A4 (en) 2004-02-25
AU5741300A (en) 2001-01-02
HUP0201571A3 (en) 2002-11-28
HUP0201571A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
BR9913903A (pt) Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica
BR0211810A (pt) Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
PT687251E (pt) Derivados de 1,3-di-hidro-indol-2-ona, substituidos na posicao 3 por um grupo azoto , como agonistas ou antagonistas da vasopressina e/ou ocitocina
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
BR9807083A (pt) Antagonistas ao receptor de il-8
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
BR9812381A (pt) Peptopiranosilnucleosìdeo, seu preparo e uso
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
BR9813208A (pt) Antagonista receptor de vitronectina
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR9814042A (pt) &#34;compostos de tiofeno condensados e seu uso farmacêutico&#34;
BR0206237A (pt) Uso de um composto de carboestiril
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9801132A (pt) N-heterociclos fundidos, substituìdos com benzilóxi, processo para a sua preparação e seu uso como antagonistas de receptor de bradiquinina.
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
BR9807085A (pt) Antagonistas de receptor de il-8

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.